Friday , 22 November 2024
Home Health Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy
Health

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy

Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study.

The post Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy appeared first on MedCity News.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin

Kura Oncology already had a broad development plan for ziftomenib in leukemias,...

How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired?

Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace...

Everything You Need to Know About Hip Replacement Surgery in India

Hip replacement surgery is one of the most common and successful medical...

Speculation on RFK Jr. as HHS Secretary

From Tyler Cowen at Marginal Revolution: One of the problems with an...